Title |
A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains
|
---|---|
Published in |
Retrovirology, December 2012
|
DOI | 10.1186/1742-4690-9-104 |
Pubmed ID | |
Authors |
Lu Lu, Chungen Pan, Yuan Li, Hong Lu, Wu He, Shibo Jiang |
Abstract |
Most currently approved anti-HIV drugs (e.g., reverse transcriptase inhibitors, protease inhibitors and fusion/entry inhibitors) must act inside or on surface of the target cell to inhibit HIV infection, but none can directly inactivate virions away from cells. Although soluble CD4 (sCD4) can inactivate laboratory-adapted HIV-1 strains, it fails to reduce the viral loads in clinical trials because of its low potency against primary isolates and tendency to enhance HIV-1 infection at low concentration. Thus, it is essential to design a better HIV inactivator with improved potency for developing new anti-HIV therapeutics that can actively attack the virus in the circulation before it attaches to and enter into the target cell. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 67% |
Members of the public | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 25 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 24% |
Researcher | 4 | 16% |
Student > Postgraduate | 3 | 12% |
Student > Master | 3 | 12% |
Student > Doctoral Student | 2 | 8% |
Other | 4 | 16% |
Unknown | 3 | 12% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 6 | 24% |
Medicine and Dentistry | 5 | 20% |
Agricultural and Biological Sciences | 3 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
Chemistry | 2 | 8% |
Other | 4 | 16% |
Unknown | 3 | 12% |